---
title: "Theraclion Reports 44% Turnover Growth and Expands Pay per Use Model in 2025"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/274185527.md"
datetime: "2026-01-29T17:30:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274185527.md)
  - [en](https://longbridge.com/en/news/274185527.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274185527.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/274185527.md) | [English](https://longbridge.com/en/news/274185527.md)


# Theraclion Reports 44% Turnover Growth and Expands Pay per Use Model in 2025

Theraclion SA reported a turnover of €1.19 million for 2025, representing a 44% increase compared to €830,000 in the previous year. The company recorded sales growth in several segments, including a 30% rise in sales of Pay per Use (PPU) and consumables to €626,000, and a 10% increase in sales of services to €218,000. Merchandise sales in China decreased by 22% to €348,000, while sales of Sonovein® systems reached €379,000. The company also noted a credit note for Echopulse of €680,000. As of December 31, 2025, Theraclion’s available cash stood at €3.4 million, further supplemented by a €0.9 million reimbursement from the French tax authorities in January 2026. The current financial outlook extends to the end of May 2026, with the company taking steps to secure additional funding to support its business plan and growth objectives. Theraclion highlighted progress in clinical validation, regulatory milestones in the United States, Europe, and China, and increased commercial activity, including new contracts and expansion of its prospect list. The next financial results are scheduled for release on April 16, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260129473447) on January 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-HK/quote/XLV.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [Atara Biotherap (ATRA.US)](https://longbridge.com/zh-HK/quote/ATRA.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-HK/quote/ARKG.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)

## 相關資訊與研究

- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/zh-HK/news/278565253.md)
- [Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel | ATRA Stock News](https://longbridge.com/zh-HK/news/278879649.md)
- [Edgewise Therapeutics Completes Key Renal Study for EDG-7500, Setting Up Next Steps for Investors](https://longbridge.com/zh-HK/news/278917336.md)
- [C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology | INKT Stock News](https://longbridge.com/zh-HK/news/278521475.md)
- [Galecto Rebrands as Damora Therapeutics with New Ticker](https://longbridge.com/zh-HK/news/278556054.md)